US20200249246A1 - Adrenomedullin to guide therapy of blood pressure decline - Google Patents
Adrenomedullin to guide therapy of blood pressure decline Download PDFInfo
- Publication number
- US20200249246A1 US20200249246A1 US16/781,226 US202016781226A US2020249246A1 US 20200249246 A1 US20200249246 A1 US 20200249246A1 US 202016781226 A US202016781226 A US 202016781226A US 2020249246 A1 US2020249246 A1 US 2020249246A1
- Authority
- US
- United States
- Prior art keywords
- adm
- seq
- proadm
- fragments
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101800004616 Adrenomedullin Proteins 0.000 title description 153
- 102000004379 Adrenomedullin Human genes 0.000 title description 148
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title description 143
- 238000002560 therapeutic procedure Methods 0.000 title description 21
- 230000036772 blood pressure Effects 0.000 title description 10
- 230000007423 decrease Effects 0.000 title description 3
- 239000012634 fragment Substances 0.000 claims abstract description 53
- 150000001413 amino acids Chemical class 0.000 claims abstract description 33
- 210000001124 body fluid Anatomy 0.000 claims abstract description 12
- 238000003556 assay Methods 0.000 claims description 59
- 210000002381 plasma Anatomy 0.000 claims description 36
- 239000011230 binding agent Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 9
- 230000035939 shock Effects 0.000 claims description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 229940124572 antihypotensive agent Drugs 0.000 abstract description 53
- 239000005526 vasoconstrictor agent Substances 0.000 abstract description 53
- 238000000034 method Methods 0.000 abstract description 27
- 238000002637 fluid replacement therapy Methods 0.000 abstract description 20
- 238000000338 in vitro Methods 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 24
- 206010040047 Sepsis Diseases 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 239000000975 dye Substances 0.000 description 13
- 206010040070 Septic Shock Diseases 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 11
- 230000036303 septic shock Effects 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 6
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010007556 Cardiac failure acute Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 206010007625 cardiogenic shock Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 102000046663 human ADM Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 208000012866 low blood pressure Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000004768 organ dysfunction Effects 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 3
- 102000034567 proadrenomedullin Human genes 0.000 description 3
- 108010012004 proadrenomedullin Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 206010003402 Arthropod sting Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010007617 Cardio-respiratory arrest Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 241000186652 Sporosarcina ureae Species 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 238000002671 oral rehydration therapy Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000532370 Atla Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- -1 Texas Red Chemical class 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 1
- 229960000692 levosimendan Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 108010049361 preproadrenomedullin Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- JCVQBJTWWDYUFQ-MRUTUVJXSA-N selepressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 JCVQBJTWWDYUFQ-MRUTUVJXSA-N 0.000 description 1
- 229950008103 selepressin Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Oncology (AREA)
Abstract
Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps:
-
- Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject
- Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.
Description
- Subject matter of the present invention is an in vitro method for identifying a subject in need of administration of fluid resuscitation or a vasopressor comprising the following steps:
-
- Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject
- Correlating said level with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.
- The peptide adrenomedullin (ADM) was described for the first time in Kitamura et al., (cf. 1; numerical data are based on the attached list of references) as a novel hypotensive peptide comprising 52 amino acids, which had been isolated from a human pheochromocytoma. In the same year, cDNA coding for a precursor peptide comprising 185 amino acids and the complete amino acid sequence of this precursor peptide were also described. The precursor peptide, which comprises, inter alia, a signal sequence of 21 amino acids at the N-terminus, is referred to as “preproadrenomedullin” (pre-proADM). Pre-proADM comprises 185 amino acids. The mature ADM is displayed in SEQ ID No. 4 and ADM-Gly is displayed in SEQ No. 5.
- The mature peptide adrenomedullin (ADM) is an amidated peptide which comprises 52 amino acids (SEQ ID No: 4) and which comprises the amino acids 95 to 146 of pre-proADM, from which it is formed by proteolytic cleavage. To date, substantially only a few fragments of the peptide fragments formed in the cleavage of the pre-proADM have been more exactly characterized, in particular the physiologically active peptides adrenomedullin (ADM) and “PAMP”, a peptide comprising 20 amino acids (22-41) which follows the 21 amino acids of the signal peptide in pre-proADM. For both ADM and PAMP, physiologically active sub-fragments have furthermore been discovered and investigated in more detail. The discovery and characterization of ADM in 1993 triggered intensive research activity and a flood of publications, the results of which have recently been summarized in various review articles, in the context of the present description, reference being made in particular to the articles to be found in an issue of “Peptides” devoted to ADM (Peptides 22 (2001)), in particular (2) and (3). A further review is (4). In the scientific investigations to date, it has been found, inter alia, that ADM may be regarded as a polyfunctional regulatory peptide. It is released into the circulation in an inactive form extended by glycine (5). There is also a binding protein (6) which is specific for ADM and probably likewise modulates the effect of ADM.
- Those physiological effects of ADM as well as of PAMP which are of primary importance in the investigations to date were the effects influencing blood pressure. Thus, ADM is an effective vasodilator, it being possible to associate the hypotensive effect with in particular peptide segments in the C-terminal part of ADM.
- It has furthermore been found that the above-mentioned further physiologically active peptide PAMP formed from pre-proADM likewise exhibits a hypotensive effect, even if it appears to have an action mechanism differing from that of ADM (cf. in addition to the above-mentioned review articles (3) and (4) also (7), (8) or (9) and (10)).
- It has furthermore been found that the concentrations of ADM which can be measured in the circulation and other biological fluids are, in a number of pathological states, significantly above the concentrations to be found in healthy control persons. Thus, the ADM level in patients with congestive heart failure, myocardial infarction, kidney diseases, hypertensive disorders, Diabetes mellitus, in the acute phase of shock and in sepsis and septic shock are significantly increased, although to different extents. The PAMP concentrations are also increased in some of said pathological states, but the plasma levels are reduced relative to ADM ((3); page 1702).
- It is furthermore known that unusually high concentrations of ADM are to be observed in sepsis or in septic shock (cf. (3) and (11), (12), (13), (14) and (15)). The findings are related to the typical hemodynamic changes which are known as typical phenomena of the course of a disease in patients with sepsis and other severe syndromes, such as, for example, SIRS.
- Although it is assumed that ADM and PAMP are formed from the same precursor peptide, pre-proADM, in which the amino acid sequences corresponding to these peptides are present as partial peptides in equimolar amounts, the concentrations of ADM or PAMP measurable in biological fluids apparently differ. This is nothing unusual.
- Thus, the measurable concentrations of different degradation products of one and the same precursor peptide may be different, for example, because they are the result of different competing degradation pathways which, for example in the case of different pathological states, lead to different fragmentation of a precursor peptide and hence to different degradation products. Certain partial peptides contained in the precursor peptide may be formed as free peptides or may not be formed, and/or different peptides are formed in different ways and in different amounts. Even if only a single degradation pathway is taken for processing a precursor peptide, and hence all degradation products originate from one and the same precursor peptide and must have been formed per se primarily in equimolar amounts, the steady state concentrations of different partial peptides and fragments measurable in biological fluids may be very different, namely, for example, when individual ones thereof are formed at a different rate and/or have different individual stabilities (lifetimes) in the respective biological fluid, or if they are removed from circulation on the basis of different clearance mechanisms and/or at different clearance rates.
- Adrenomedullin plays pivotal roles during sepsis development ((16), (17)) and in numerous acute and chronic diseases ((18), (4)).
- Several methods have been described to measure circulating levels of ADM: Either ADM directly or indirectly by determining a more stable fragment of its cognate precursor peptide. Very recently a method has been published describing an assay to measure circulating mature ADM (Di Somma S, Magrini L, Travaglino F, Lalle I, Fiotti N, Cervellin G, Avanzi G C, Lupia E, Maisel A, Hein F et al: Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clinical chemistry and laboratory medicine: CCLM/FESCC 2013:1-9.)
- Other methods to quantify fragments derived from the ADM precursor have been described, e.g. the measurement of MR-proADM (Morgenthaler N G, Struck J, Alonso C, Bergmann A.Clin Chem. 2005 October; 51(10):1823-9.), PAMP (Washimine H, Kitamura K, Ichiki Y, Yamamoto Y, Kangawa K, Matsuo H, Eto T. Biochem Biophys Res Commun. 1994 Jul. 29; 202(2):1081-7.), CT-proADM (EP211552). A commercial assay for the measurement of MR-proADM is available (BRAHMS MR-proADM KRYPTOR; BRAHMS GmbH, Hennigsdorf, Germany) (Clin Biochem. 2009 May; 42(7-8):725-8. doi: 10.1016/j.clinbiochem.2009.01.002. Epub 2009 Jan 23).
- Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR (Caruhel P, Mazier C, Kunde J, Morgenthaler N G, Darbouret B.). As these peptides are generated in a stoichiometric ratio from the same precursor, their plasma levels are correlated to a certain extent.
- Only in a few studies plasma ADM has been measured in patients with systemic inflammation, sepsis, severe sepsis or septic shock, and levels have been correlated with hemodynamic parameters:
- In a study by Hirata et al. plasma ADM in septic patients was found to be correlated with heart rate, right arterial pressure, but not with mean arterial pressure (MAP) (Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, Marumo F: Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. The Journal of clinical endocrinology and metabolism 1996, 81(4):1449-1453).
- Nishio et al. reported that increased plasma concentrations of ADM were correlated with relaxation of vascular tone in patients with septic shock (correlation with cardiac index, stroke volume index, heart rate, decrease in diastolic blood pressure, systemic vascular resistance index and pulmonary vascular resistance index), however there was no significant correlation with mean blood pressure [19].
- In healthy subjects under exercise a significant negative correlation of plasma ADM and MAP was found [20].
- Nothing is known about the association of circulating ADM or related peptide levels as pro-ADM or fragments thereof and the requirements for fluid resuscitation and vasopressors in patients developing shock. This is an unmet medical need as vasopressors are usually given very late when the condition of the patient is very serious. It is an unmet medical need to identify those patients in need of fluid resuscitation and vasopressors before the condition of the patient is very serious. It is an unmet medical need to predict the requirement for fluid resuscitation and vasopressor therapy earlier than by blood pressure measurement applying the cut-off value of 65 mm Hg, as recommended in the guidelines [21]. If blood pressure fells, this leads to diminished oxygen supply, organ dysfunction and death. It is thus an unmet need to early identify patients who are at risk to develop a blood pressure decline. If such patients could be identified earlier, other, e.g. higher cut-off values for mean arterial pressure could be applied to initiate fluid resuscitation and vasopressor therapy. Higher threshold-levels are <70 mm Hg, preferably <75 mm Hg. This means that therapy starts already above 65 mmHg
- Subject matter of the present invention is an in vitro method for identifying a subject in need of fluid resuscitation or administration of a vasopressor comprising the following steps:
-
- Determining the level of proADM and/or fragments thereof having at least 6 amino acids in a bodily fluid of said subject
- Correlating said level with the need of said subject or patient for fluid resuscitation or administration of a vasopressor wherein said subject or patient is identified as having such a need if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold.
- In one embodiment of the methods according to the invention the subject has a mean arterial pressure >65 mm Hg. Further, said subject may have a mean arterial pressure <75 mmg Hg, in another embodiment <70 mmg Hg.
- In one embodiment of the invention said method is a method for the early identification of fluid resuscitation or administration of a vasopressor wherein earlier means earlier than by blood pressure measurement applying a cut-off value of 65 mmg Hg or before the blood pressure dropped to 65 mmg Hg.
- A bodily fluid according to the present invention is in one particular embodiment a blood sample. A blood sample may be selected from the group comprising whole blood, serum and plasma.
- In a specific embodiment of the invention said proADM and/or fragments thereof having at least 6 amino acids is/are selected from the group comprising:
-
(proADM): 164 amino acids (22-185 of preproADM) SEQ ID No. 1 ARLDVASEF RKKWNKWALS RGKRELRMSS SYPTGLADVK AGPAQTLIRP QDMKGASRSP EDSSPDAARI RVKRYRQSMN NFQGLRSFGC RFGTCTVQKL AHQIYQFTDK DKDNVAPRSK ISPQGYGRRR RRSLPEAGPG RTLVSSKPQA HGAPAPPSGS APHFL (Proadrenomedullin N-20 terminal peptide): Peptides 22-41 SEQ ID No. 2 ARLDVASEF RKKWNKWALS R (MidregionalproAdrenomedullin, MR-proADM): Peptides45-92 SEQ ID No. 3 ELRMSS SYPTGLADVK AGPAQTLIRP QDMKGASRSP EDSSPDAARI RV (mature Adrenomedullin (mature ADM); amidated): Peptides 95-146-CONH2 SEQ ID No. 4 YRQSMN NFQGLRSFGC RFGTCTVQKL AHQIYQFTDK DKDNVAPRSK ISPQGY-CONH2 (Adrenomedullin 1-52-Gly (ADM 1-52-Gly)): Peptides 95-147 SEQ ID No. 5 YRQSMN NFQGLRSFGC RFGTCTVQKL AHQIYQFTDK DKDNVAPRSK ISPQGYG (C-terminal proAdrenomedullin, CT-proADM): Peptides 148-185 SEQ ID No. 6 RRR RRSLPEAGPG RTLVSSKPQA HGAPAPPSGS APHFL - In a specific embodiment of the invention said proADM and/or fragments thereof having at least 6 amino acids is/are selected from the group comprising mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5) and MR-proADM (SEQ ID No. 3) and CT-proADM (SEQ ID No. 6).
- In a specific embodiment of the invention either the level of mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5)—immunoreactivity or the level of MR-proADM (SEQ ID No. 3) immunoreactivity or the level of CT-proADM (SEQ ID No. 6) immunoreactivity is determined and correlated with the need of said patient for fluid resuscitation or administration of a vasopressor wherein said patient is identified as having such a need if the level of mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5)—immunoreactivity or the level of MR-proADM (SEQ ID No. 3) immunoreactivity or the level of CT-proADM (SEQ ID No. 6) immunoreactivity in the bodily fluid of said subject is above a threshold.
- In a specific embodiment of the invention the level of pro-ADM and/or fragments thereof is determined by using at least one binder selected from the group: a binder that binds to a region comprised within the following sequence of mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5) and a second binder that binds to a region comprised within the sequence of mature ADM (SEQ ID NO. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5).
- In a specific embodiment of the invention the level of pro-ADM and/or fragments thereof is determined by using at least one binder selected from the group: a binder that binds to a region comprised within the sequence of MR-proADM (SEQ ID No. 3) and a second binder that binds to a region comprised within the sequence of MR-proADM (SEQ ID No. 3)
- In a specific embodiment of the invention the level of pro-ADM and/or fragments thereof is determined by using at least one binder selected from the group: a binder that binds to a region comprised within the sequence of CT-proADM (SEQ ID No. 6) and a second binder that binds to a region comprised within the sequence of CT-pro ADM (SEQ ID No. 6).
- In a specific embodiment of the invention an assay is used for determining the level of proADM and/or fragments thereof having at least 6 amino acids wherein the assay sensitivity of said assay is able to quantify the ADM of healthy subjects and is <70 pg/ml, preferably <40 pg/ml and more preferably <10 pg/ml.
- In a specific embodiment of the invention said binder exhibits an binding affinity to proADM and/or fragments thereof of at least 107 M−1, preferred 108 M−1, preferred affinity is greater than 109 M−1, most preferred greater than 1010 M−1 A person skilled in the art knows that it may be considered to compensate lower affinity by applying a higher dose of compounds and this measure would not lead out-of-the-scope of the invention.
- To determine the affinity of the antibodies to Adrenomedullin, the kinetics of binding of Adrenomedullin to immobilized antibody was determined by means of label-free surface plasmon resonance using a Biacore 2000 system (GE Healthcare Europe GmbH, Freiburg, Germany). Reversible immobilization of the antibodies was performed using an anti-mouse Fc antibody covalently coupled in high density to a CM5 sensor surface according to the manufacturer's instructions (mouse antibody capture kit; GE Healthcare), (22).
- In a specific embodiment of the invention said binder is selected from the group comprising an antibody or an antibody fragment or a non-Ig scaffold binding to proADM and/or fragments thereof.
- In a specific embodiment of the invention an assay is used for determining the level of proADM and/or fragments thereof having at least 6 amino acids wherein such assay is a sandwich assay, preferably a fully automated assay.
- In one embodiment of the invention it may be a so-called POC-test (point-of-care) that is a test technology which allows performing the test within less than 1 hour near the patient without the requirement of a fully automated assay system. One example for this technology is the immunochromatographic test technology.
- In one embodiment of the invention such an assay is a sandwich immunoassay using any kind of detection technology including but not restricted to enzyme label, chemiluminescence label, electrochemiluminescence label, preferably a fully automated assay. In one embodiment of the invention such an assay is an enzyme labeled sandwich assay. Examples of automated or fully automated assay comprise assays that may be used for one of the following systems: Roche Elecsys®, Abbott Architect®, Siemens Centauer®, Brahms Kryptor®, BiomerieuxVidas®, Alere Triage®.
- A variety of immunoassays are known and may be used for the assays and methods of the present invention, these include: radioimmunoassays (“RIA”), homogeneous enzyme-multiplied immunoassays (“EMIT”), enzyme linked immunoadsorbent assays (“ELISA”), apoenzyme reactivation immunoassay (“ARIS”), dipstick immunoassays and immuno-chromotography assays.
- In a specific embodiment of the invention at least one of said two binders is labeled in order to be detected.
- The preferred detection methods comprise immunoassays in various formats such as for instance radioimmunoassay (RIA), chemiluminescence- and fluorescence-immunoassays, Enzyme-linked immunoassays (ELISA), Luminex-based bead arrays, protein microarray assays, and rapid test formats such as for instance immunochromatographic strip tests.
- In a preferred embodiment said label is selected from the group comprising chemiluminescent label, enzyme label, fluorescence label, radioiodine label.
- The assays can be homogenous or heterogeneous assays, competitive and non-competitive assays. In one embodiment, the assay is in the form of a sandwich assay, which is a non-competitive immunoassay, wherein the molecule to be detected and/or quantified is bound to a first antibody and to a second antibody. The first antibody may be bound to a solid phase, e.g. a bead, a surface of a well or other container, a chip or a strip, and the second antibody is an antibody which is labeled, e.g. with a dye, with a radioisotope, or a reactive or catalytically active moiety. The amount of labeled antibody bound to the analyte is then measured by an appropriate method. The general composition and procedures involved with “sandwich assays” are well-established and known to the skilled person (23).
- In another embodiment the assay comprises two capture molecules, preferably antibodies which are both present as dispersions in a liquid reaction mixture, wherein a first labelling component is attached to the first capture molecule, wherein said first labelling component is part of a labelling system based on fluorescence- or chemiluminescence-quenching or amplification, and a second labelling component of said marking system is attached to the second capture molecule, so that upon binding of both capture molecules to the analyte a measurable signal is generated that allows for the detection of the formed sandwich complexes in the solution comprising the sample.
- In another embodiment, said labeling system comprises rare earth cryptates or rare earth chelates in combination with fluorescence dye or chemiluminescence dye, in particular a dye of the cyanine type.
- In the context of the present invention, fluorescence based assays comprise the use of dyes, which may for instance be selected from the group comprising FAM (5-or 6-carboxyfluorescein), VIC, NED, Fluorescein, Fluoresceinisothiocyanate (FITC), IRD-700/800, Cyanine dyes, such as CY3, CYS, CY3.5, CY5.5, Cy7, Xanthen, 6-Carboxy-2′,4′,7′,4,7-hexachlorofluorescein (HEX), TET, 6-Carboxy-4′,5′-dichloro-2′,7′-dimethodyfluorescein (JOE), N,N,N′,N′-Tetramethyl-6-carboxyrhodamine (TAMRA), 6-Carboxy-X-rhodamine (ROX), 5-Carboxyrhodamine-6G (R6G5), 6-carboxyrhodamine-6G (RG6), Rhodamine, Rhodamine Green, Rhodamine Red, Rhodamine 110, BODIPY dyes, such as BODIPY TMR, Oregon Green, Coumarins such as Umbelliferone, Benzimides, such as Hoechst 33258; Phenanthridines, such as Texas Red, Yakima Yellow, Alexa Fluor, PET, Ethidiumbromide, Acridinium dyes, Carbazol dyes, Phenoxazine dyes, Porphyrine dyes, Polymethin dyes, and the like.
- In the context of the present invention, chemiluminescence based assays comprise the use of dyes, based on the physical principles described for chemiluminescent materials in (24). Preferred chemiluminescent dyes are acridiniumesters.
- As mentioned herein, an “assay” or “diagnostic assay” can be of any type applied in the field of diagnostics. Such an assay may be based on the binding of an analyte to be detected to one or more capture probes with a certain affinity. Concerning the interaction between capture molecules and target molecules or molecules of interest, the affinity constant is preferably greater than 108 M−1.
- In the context of the present invention, “binder molecules” are molecules which may be used to bind target molecules or molecules of interest, i.e. analytes (i.e. in the context of the present invention PCT and fragments thereof), from a sample. Binder molecules must thus be shaped adequately, both spatially and in terms of surface features, such as surface charge, hydrophobicity, hydrophilicity, presence or absence of lewis donors and/or acceptors, to specifically bind the target molecules or molecules of interest. Hereby, the binding may for instance be mediated by ionic, van-der-Waals, pi-pi, sigma-pi, hydrophobic or hydrogen bond interactions or a combination of two or more of the aforementioned interactions between the capture molecules and the target molecules or molecules of interest. In the context of the present invention, binder molecules may for instance be selected from the group comprising a nucleic acid molecule, a carbohydrate molecule, a PNA molecule, a protein, an antibody, a peptide or a glycoprotein. Preferably, the binder molecules are antibodies, including fragments thereof with sufficient affinity to a target or molecule of interest, and including recombinant antibodies or recombinant antibody fragments, as well as chemically and/or biochemically modified derivatives of said antibodies or fragments derived from the variant chain with a length of at least 12 amino acids thereof.
- Chemiluminescent label may be acridinium ester label, steroid labels involving isoluminol labels and the like.
- Enzyme labels may be lactate dehydrogenase (LDH),creatinekinase (CPK), alkaline phosphatase, aspartateaminotransferace (AST), alanine aminotransferace (ALT),acid phosphatase, glucose-6-phosphate dehydrogenase and so on.
- In one embodiment of the invention at least one of said two binders is bound to a solid phase as magnetic particles, and polystyrene surfaces.
- In a specific embodiment of the invention at least one of said two binders is bound to a solid phase.
- In one embodiment of the invention the concentration of ADM or fragments thereof measured in the sample is in the range between 10-500 pg/ml in plasma or blood.
- The ADM levels of the present invention or proADM levels or fragments thereof, respectively, have been determined with the described ADM assay, as outlined in the examples (or proADM or fragments thereof assays, respectively). The above mentioned values might be different in other ADM assays (or proADM or fragments thereof assays, respectively), depending upon their way of calibration. The above mentioned values shall apply for such differently calibrated ADM assays accordingly, taking into account the differences in calibration. ADM assays could be calibrated by correlation and adjustment via their normal ranges (healthy population). (or proADM or fragments thereof assays, respectively) Alternatively, commercially available control samples could be used for adjustment of different calibrations (ICI Diagnostics, Berlin, Germany)
- With the described ADM assay, the median of of a normal population has been determined to be 24.7 pg/mL.
- In a specific embodiment of the invention a threshold for plasma ADM of 90 pg/ml, preferably 70 pg/ml is applied.
- In a specific embodiment of the invention a threshold for plasma MR-proADM of 0.9 nmol/L, preferably 0.7 nmol/L is applied
- In a specific embodiment of the invention a threshold for plasma CT-proADM of 1.0 nmol/L, preferably 0.8 nmol/L is applied.
- If the level of plasma ADM or plasma MR-proADM or plasma CT-proADM is above said threshold the person might be in need of treatment with a vasopressor.
- In a specific embodiment of the invention said sample is selected from the group comprising human citrate plasma, heparin plasma, EDTA plasma, whole blood.
- The subject that may be in need of fluid resuscitation or treatment with a vasopressor may suffer from a condition selected from the group comprising: patients at risk to develop physiological shock states, as described in more detail below, but also infections, SIRS, sepsis, heart failure, cardiopulmonary arrest, postoperative cardiac surgery, right ventricular infarction, bradyarrhythmias, polytrauma, burns, kidney injury.
- This type of shock can be caused by:
-
- Severe bleeding.
- Pulmonary embolus (a blood clot in the lungs).
- Severe vomiting and diarrhoea.
- Spinal injury.
- Poisoning.
- There are also specific types of physiological shock, with very particular symptoms.
- Cardiogenic shock:
- Cardiogenic shock occurs when the heart is severely damaged—by a major heart attack, for example—and is no longer able to pump blood around the body properly, causing very low blood pressure. This develops after about eight per cent of heart attacks. It can be difficult to treat, but drugs may be given to make the heart beat stronger. This may be enough to bring someone through the worst until the heart can mend itself, but cardiogenic shock is still fatal in as many as eight out of ten cases. New treatments to ‘revascularise’ or restore blood flow to the heart muscle are improving survival rates.
- Septic shock:
- This occurs when an overwhelming bacterial infection causes blood pressure to drop. It's fatal in more than 50% of cases. Although it's caused by bacterial infection, treating septic shock with antibiotics is far from simple, because the bacteria release massive amounts of toxin when they are killed off, which initially makes the shock worse. It must always be treated in hospital where the correct drugs and fluid support can be given. One type of septic shock is toxic shock syndrome—a rare but severe illness caused by certain strains of the bacteria Staphylococcus aureus.
- Anaphylactic shock:
- Anaphylactic shock is a severe allergic reaction. Common triggers include bee and wasp stings, nuts, shellfish, eggs, latex and certain medications, including penicillin. Symptoms include:
-
- Burning and swelling of the lips and tongue.
- Difficulty breathing (like in an asthma attack).
- Red, itchy or blistered skin, sneezing.
- Watery eyes.
- Nausea.
- Anxiety.
- Anaphylaxis requires urgent treatment in hospital. People at risk should always carry an emergency anaphylaxis treatment kit that includes adrenaline.
- Sepsis and its escalated forms (severe sepsis, septic shock) continue to be a major medical problem, with mortality rates ranging from 30 to 70%. Despite advances in supportive care, each year 750,000 people develop sepsis and 225,000 die in the United States alone, and the incidence of sepsis is rising at rates between 1.5% and 8% per year [4-6]. In order to save the life of a septic patient, it is essential to first timely fight the infectious stimulus by antibiotics or other measures, and second, to timely recognize escalation of the situation, e.g. when severe sepsis proceeds to septic shock, because only then suitable vasopressor therapy can be initiated early. Any delay would increase the risk of the patient to die.
- The conditions under which it is recommended to initiate a fluid resuscitation or vasopressor/inotrope therapy in patients progressing to septic shock are described in the guidelines of the Surviving Sepsis Campaign [3]: It is recommended to apply vasopressors for hypotension that does not respond to initial fluid resuscitation to maintain a mean arterial pressure (MAP) of ≥65 mm Hg. The guideline also talks about which vasopressor/inotrope to apply preferentially when. The current consensus view is: Norepinephrine as the first choice vasopressor. Epinephrine (added to and potentially substituted for norepinephrine) when an additional agent is needed to maintain adequate blood pressure. Vasopressin 0.03 units/minute can be added to norepinephrine (NE) with intent of either raising MAP or decreasing NE dosage (UG). In general, currently used vasopressors and inotropes in clinical practice are [7, 8]:
- Catecholamines (Dopamine, Dobutamine, Norepinephrine, Epinephrine, Isoproterenol, Phenylephrine), Phosphodiesterase III inhibitors (Milrinone, Amrinone), Vasopressin, Levosimendan.
- Additionally, other vasoactive compounds are under development, such as for instance Selepressin, a selective vasopressin V la receptor agonist [9] and anti-Adrenomedullin antibodies.
- Other compounds have been investigated, but clinical data available for these treatments are sparse, and fairly equivocal results of these approaches have been obtained in larger trials [10]. These are inhibitors of ATP-dependent K+-channels (glibenclamide; [11, 12]) of NOS (NG-monomethyl-L-arginine [13, 14]) and of cGMP (methylene blue [15, 16]).
- Vasopressors and inotropes are clinically applied to treat and prevend various physiological shock types, but also cardiovascular diseases (congestive heart failure, cardiopulmonary arrest, postoperative cardiac surgery, right ventricular infarction, bradyarrhythmias) [7]
- Since blood pressure is always monitored in patients that present in a critical condition, from a clinical point of view, patients with values above the respective thresholds e.g. high ADM (>70 pg/ml) without vasopressor need at presentation should be vasopressor treated by adapting the points of decision from <66 mmHg MAP to e.g. <75 mmHg aiming earlier support of circulation to protect patient from low blood pressure associated organ dysfunctions and subsequent high mortality. Using this rule for patients >70 pg/ml ADM and treating with vasopressors at MAP <=75 mmHg, patients (Group 3) would be treated in average 1,6 days before standard of care treatment (<=66 mmHg).
- Thus, in a specific embodiment of the present invention said patient is identified as having a need of administration of a vasopressor if the level of proADM and/or fragments thereof having at least 6 amino acids in the bodily fluid of said subject is above a threshold and if the patient has a </=75 mmHg MAP but preferably >66 mmHg, more preferably >70 mmHg MAP.
- In a specific embodiment of the invention a threshold for plasma ADM of 90 pg/ml, preferably 70 pg/ml is applied and/or the patient has a <=/75 mmHg MAP but preferably >66mmHg, more preferably >70 mmHg MAP.
- In a specific embodiment of the invention a threshold for plasma MR-proADM of 0.9 nmol/L, preferably 0.7 nmol/L is applied and/or the patient has a </=75 mmHg MAP but preferably >66 mmHg, more preferably >70 mmHg MAP.
- In an specific embodiment of the invention a threshold for plasma CT proADM of 1.0 nmol/L preferably 0.8 nmol/L is applied and/or the patient has a </=75 mmHg MAP but preferably >66 mmHg, more preferably >70 mmHg MAP.
- If the level of plasma ADM or plasma MR-proADM or plasma CT proADM is above said threshold and/or if the patient has a </=75 mmHg MAP but preferably >66 mmHg, more preferably >70 mmHg MAP the person might be in need of treatment with a vasopressor.
- Fluid replacement or fluid resuscitation is the medical practice of replenishing bodily fluid lost through sweating, bleeding, fluid shifts or other pathologic processes as above described. Fluids can be replaced via oral administration (drinking), intravenous administration, rectally, or by hypodermoclysis, the direct injection of fluid into the subcutaneous tissue. Fluids administered by the oral and hypodermic routes are absorbed more slowly than those given intravenously. Oral rehydration therapy (ORT) is a simple treatment for dehydration associated with diarrhea, particularly gastroenteritis/gastroenteropathy, such as that caused by cholera or rotavirus. ORT consists of a solution of salts and sugars which is taken by mouth.
- In severe dehydration, intravenous fluid replacement is preferred, and may be lifesaving. It is especially useful where there is depletion of fluid both in the intracellular space and the vascular spaces.
- Fluid replacement is also indicated in fluid depletion due to any of the above described conditions.
- An antibody according to the present invention is a protein including one or more polypeptides substantially encoded by immunoglobulin genes that specifically binds an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha (IgA), gamma (IgG1, IgG2, IgG3, IgG4), delta (IgD), epsilon (IgE) and mu (IgM) constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin light chains are generally about 25 Kd or 214 amino acids in length. Full-length immunoglobulin heavy chains are generally about 50 Kd or 446 amino acid in length.
- Light chains are encoded by a variable region gene at the NH2-terminus (about 110 amino acids in length) and a kappa or lambda constant region gene at the COOH-terminus. Heavy chains are similarly encoded by a variable region gene (about 116 amino acids in length) and one of the other constant region genes.
- The basic structural unit of an antibody is generally a tetramer that consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions bind to an antigen, and the constant regions mediate effector functions. Immunoglobulins also exist in a variety of other forms including, for example, Fv, Fab, and (Fab′)2, as well as bifunctional hybrid antibodies and single chains (e.g., Lanzavecchiaet al., Eur. J. Immunol. 17:105,1987; Huston et al., Proc. Natl. Acad. Sci. U.S.A., 85:5879-5883, 1988; Bird et al., Science 242:423-426, 1988; Hood et al., Immunology, Benjamin, N.Y., 2nd ed., 1984; Hunkapiller and Hood, Nature 323:15-16,1986). An immunoglobulin light or heavy chain variable region includes a framework region interrupted by three hypervariable regions, also called complementarity determining regions (CDR's) (see, Sequences of Proteins of Immunological Interest, E. Kabatet al., U.S. Department of Health and Human Services, 1983). As noted above, the CDRs are primarily responsible for binding to an epitope of an antigen. An immune complex is an antibody, such as a monoclonal antibody, chimeric antibody, humanized antibody or human antibody, or functional antibody fragment, specifically bound to the antigen.
- Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes belonging to different species. For example, the variable segments of the genes from a mouse monoclonal antibody can be joined to human constant segments, such as kappa and
gamma 1 or gamma 3. In one example, a therapeutic chimeric antibody is thus a hybrid protein composed of the variable or antigen-binding domain from a mouse antibody and the constant or effector domain from a human antibody, although other mammalian species can be used, or the variable region can be produced by molecular techniques. Methods of making chimeric antibodies are well known in the art, e.g., see U.S. Pat. No. 5,807,715. A “humanized” immunoglobulin is an immunoglobulin including a human framework region and one or more CDRs from a non-human (such as a mouse, rat, or synthetic) immunoglobulin. The non-human immunoglobulin providing the CDRs is termed a “donor” and the human immunoglobulin providing the framework is termed an “acceptor.” In one embodiment, all the CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A “humanized antibody” is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A humanized antibody binds to the same antigen as the donor antibody that provides the CDRs. The acceptor framework of a humanized immunoglobulin or antibody may have a limited number of substitutions by amino acids taken from the donor framework. Humanized or other monoc lonal antibodies can have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. Exemplary conservative substitutions are those such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. Humanized immunoglobulins can be constructed by means of genetic engineering (e.g., see U.S. Pat. No. 5,585,089). A human antibody is an antibody wherein the light and heavy chain genes are of human origin. Human antibodies can be generated using methods known in the art. Human antibodies can be produced by immortalizing a human B cell secreting the antibody of interest Immortalization can be accomplished, for example, by EBV infection or by fusing a human B cell with a myeloma or hybridoma cell to produce a trioma cell. Human antibodies can also be produced by phage display methods (see, e.g., Dower et al., PCT Publication No. WO91/17271; McCafferty et al., PCT Publication No. WO92/001047; and Winter, PCT Publication No. WO92/20791), or selected from a human combinatorial monoclonal antibody library (see the Morphosys website). Human antibodies can also be prepared by using transgenic animals carrying a human immunoglobulin gene (for example, see Lonberget al., PCT Publication No. WO93/12227; and Kucherlapati, PCT Publication No. WO91/10741). - Thus, the antibody may have the formats known in the art. Examples are human antibodies, monoclonal antibodies, humanized antibodies, chimeric antibodies, CDR-grafted antibodies. In a preferred embodiment antibodies according to the present invention are recombinantly produced antibodies as e.g. IgG, a typical full-length immunoglobulin, or antibody fragments containing at least the F-variable domain of heavy and/or light chain as e.g. chemically coupled antibodies (fragment antigen binding) including but not limited to Fab-fragments including Fab minibodies, single chain Fab antibody, monovalent Fab antibody with epitope tags, e.g. Fab-V5Sx2; bivalent Fab (mini-antibody) dimerized with the CH3 domain; bivalent Fab or multivalent Fab, e.g. formed via multimerization with the aid of a heterologous domain, e.g. via dimerization of dHLXdomains, e.g. Fab-dHLX-FSx2; F(ab′)2-fragments, scFv-fragments, multimerized multivalent or/and multispecificscFv-fragments, bivalent and/or bispecificdiabodies, BITE® (bispecific T-cell engager), trifunctional antibodies, polyvalent antibodies, e.g. from a different class than G; single-domain antibodies, e.g. nanobodies derived from camelid or fish immunoglobulines and numerous others.
- In addition to antibodies other biopolymer scaffolds are well known in the art to complex a target molecule and have been used for the generation of highly target specific biopolymers. Examples are aptamers, spiegelmers, anticalins and conotoxins.
- In a preferred embodiment the antibody format is selected from the group comprising Fv fragment, scFv fragment, Fab fragment, scFab fragment, (Fab)2 fragment and scFv-Fc Fusion protein. In another preferred embodiment the antibody format is selected from the group comprising scFab fragment, Fab fragment, scFv fragment and bioavailability optimized conjugates thereof, such as PEGylated fragments. One of the most preferred formats is the scFab format.
- Non-Ig scaffolds may be protein scaffolds and may be used as antibody mimics as they are capable to bind to ligands or antigenes. Non-Ig scaffolds may be selected from the group comprising tetranectin-based non-Ig scaffolds (e.g. described in US 2010/0028995), fibronectin scaffolds (e.g. described in EP 1266 025; lipocalin-based scaffolds ((e.g. described in WO 2011/154420); ubiquitin scaffolds (e.g. described in WO 2011/073214), transferring scaffolds (e.g. described in US 2004/0023334), protein A scaffolds (e.g. described in EP 2231860), ankyrin repeat based scaffolds (e.g. described in WO 2010/060748), microproteins, preferably microproteins forming a cystine knot) scaffolds (e.g. described in EP 2314308), Fyn SH3 domain based scaffolds (e.g. described in WO 2011/023685) EGFR-A-domain based scaffolds (e.g. described in WO 2005/040229) and Kunitz domain based scaffolds (e.g. described in EP 1941867).
- In one embodiment of the invention antibodies according to the present invention may be produced as follows:
- A Balb/c mouse was immunized with ADM-100 μg Peptide-BSA-Conjugate at
day 0 and 14 (emulsified in 100 μl complete Freund's adjuvant) and 50 μg at day 21 and 28 (in 100 μl incomplete Freund's adjuvant). Three days before the fusion experiment was performed, the animal received 50 μg of the conjugate dissolved in 100 μl saline, given as one intraperitoneal and one intravenous injection. - Splenocytes from the immunized mouse and cells of the myeloma cell line SP2/0 were fused with lml 50% polyethylene glycol for 30s at 37° C. After washing, the cells were seeded in 96-well cell culture plates. Hybrid clones were selected by growing in HAT medium [RPMI 1640 culture medium supplemented with 20% fetal calf serum and HAT-Supplement]. After two weeks the HAT medium is replaced with HT Medium for three passages followed by returning to the normal cell culture medium.
- The cell culture supernatants were primary screened for antigen specific IgG antibodies three weeks after fusion. The positive tested microcultures were transferred into 24-well plates for propagation. After retesting, the selected cultures were cloned and recloned using the limiting-dilution technique and the isotypes were determined (see also Lane, R. D. (1985). A short-duration polyethylene glycol fusion technique for increasing production of monoclonal antibody-secreting hybridomas. J. Immunol. Meth. 81: 223-228; Ziegler, B. et al. (1996) Glutamate decarboxylase (GAD) is not detectable on the surface of rat islet cells examined by cytofluorometry and complement-dependent antibody-mediated cytotoxicity of monoclonal GAD antibodies, Horm. Metab. Res. 28: 11-15).
- Antibodies may be produced by means of phage display according to the following procedure:
- The human naive antibody gene libraries HALT/8 were used for the isolation of recombinant single chain F-Variable domains (scFv) against adrenomedullin peptide. The antibody gene libraries were screened with a panning strategy comprising the use of peptides containing a biotin tag linked via two different spacers to the adrenomedullin peptide sequence. A mix of panning rounds using non-specifically bound antigen and streptavidin bound antigen were used to minimize background of non-specific binders. The eluted phages from the third round of panning have been used for the generation of monoclonal scFv expressing E. coli strains. Supernatant from the cultivation of these clonal strains has been directly used for an antigen ELISA testing (see Hust, M., Meyer, T., Voedisch, B., Milker, T., Thie, H., El-Ghezal, A., Kirsch, M.I., Schütte, M., Helmsing, S., Meier, D., Schirrmann, T., Dübel, S., 2011. A human scFv antibody generation pipeline for proteome research. Journal of Biotechnology 152, 159-170; Schütte, M., Thullier, P., Pelat, T., Wezler, X., Rosenstock, P., Hinz, D., Kirsch, M. I., Hasenberg, M., Frank, R., Schirrmann, T., Gunzer, M., Hust, M., Dübel, S., 2009. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 4, e6625).
- Humanization of murine antibodies may be conducted according to the following procedure: For humanization of an antibody of murine origin the antibody sequence is analyzed for the structural interaction of framework regions (FR) with the complementary determining regions (CDR) and the antigen. Based on structural modeling an appropriate FR of human origin is selected and the murine CDR sequences are transplanted into the human FR. Variations in the amino acid sequence of the CDRs or FRs may be introduced to regain structural interactions, which were abolished by the species switch for the FR sequences. This recovery of structural interactions may be achieved by random approach using phage display libraries or via directed approach guided by molecular modeling (see Almagro J C, Fransson J., 2008. Humanization of antibodies. Front Biosci. 2008 Jan. 1; 13:1619-33).
- Another subject matter of the present invention is a vasopressor for use in treatment of a subject in need of fluid resuscitation or administration of a vasopressor wherein said subject is identified according to any of the above described in vitro methods including all embodiments of said in vitro methods.
-
FIG. 1 : -
FIG. 1 shows a typical ADM dose/signal curve. And an ADM dose signal curve in the presence of 100 μg/mL antibody NT-H. -
FIG. 2 - Predicting in-hospital mortality—Results from logistic regression
-
FIG. 3 - Predicting in-hospital mortality—ADM is independent from Apache and provides additional prognostic information
-
FIG. 4 - Mean arterial pressure depending on plasma ADM levels. Scatter-plot and correlation coefficient are shown for values obtained from patients at admission. Statistical significance was p<0.0001.
-
FIG. 5 - Adrenomedullin concentrations in patients at admission requiring vasopressor therapy vs patients not requiring vasopressor therapy. The difference between the two groups was statistically significant (p<0.0001).
-
FIG. 6 - ADM concentrations of patients at admission, who were treated with vasopressors on admission (“on ADM”), who did not require vasopressor therapy within the first four days after admission (“never”), and who required vasopressor therapy within the first four days after admission, but not on the day of admission (“later”). In the graph, the normal range of ADM concentrations is indicated.
-
FIG. 7 - Receiver Operator Characteristics (ROC) curve for ADM concentrations of acute heart failure patients requiring (sensitivity) and not requiring (specificity) vasopressor therapy. The area under the curve was 0.75 (p<0.0001).
- Generation of Antibodies and Determination of their Affinity Constants
- We developed mouse monoclonal antibodies binding to the N-terminal, mid-regional and C-terminal part of ADM and their affinity constants were determined (table 1).
- Peptides for Immunization
- Peptides were supplied by JPT Peptide Technologies GmbH (Berlin, Germany). Peptides were coupled to BSA using the Sulfo-SMCC crosslinking method. The crosslinking procedure was performed according the manufacturers instructions (Thermo Fisher/Pierce). The murine antibodies were generated according to the following method:
- A Balb/c mouse was immunized with 100 μg Peptide-BSA-Conjugate at
day 0 and 14 (emulsified in 100 μl complete Freund's adjuvant) and 50 μg at day 21 and 28 (in 100 μl incomplete Freund's adjuvant). Three days before the fusion experiment was performed, the animal received 50 μg of the conjugate dissolved in 100 μl saline, given as one intraperitoneal and one intra venous injection. - Splenocytes from the immunized mouse and cells of the myeloma cell line SP2/0 were fused with 1 ml 50% polyethylene glycol for 30 s at 37° C. After washing, the cells were seeded in 96-well cell culture plates. Hybrid clones were selected by growing in HAT medium [RPMI 1640 culture medium supplemented with 20% fetal calf serum and HAT-Supplement]. After two weeks the HAT medium is replaced with HT Medium for three passages followed by returning to the normal cell culture medium.
- The cell culture supernatants were primary screened for antigen specific IgG antibodies three weeks after fusion. The positive tested microcultures were transferred into 24-well plates for propagation. After retesting the selected cultures were cloned and recloned using the limiting-dilution technique and the isotypes were determined.
- (Lane, R. D. “A short-duration polyethylene glycol fusiontechnique for increasing production of monoclonal antibody-secreting hybridomas”, J. Immunol. Meth. 81: 223-228; (1985), Ziegler, B. et al. “Glutamate decarboxylase (GAD) is not detectable on the surface of rat islet cells examined by cytofluorometry and complement-dependent antibody-mediated cytotoxicity of monoclonal GAD antibodies”, Horm. Metab. Res. 28: 11-15, (1996)).
-
TABLE 1 ADM Affinity constants Antigen/Immunogen Region Designation Kd (M−1) YRQSMNNFQGLRSFGC 1-16 NT-ADM 1.6 × 109 CTVQKLAHQIYQ 21-32 MR-ADM 2 × 109 CAPRSKISPQGY-NH2 C-42-52 CT-ADM 1.1 × 109 - Monoclonal Antibody Production
- Antibodies were produced via standard antibody production methods (Marx et al, Monoclonal Antibody Production, ATLA 25, 121, 1997) and purified via Protein A. The antibody purities were >95% based on SDS gel electrophoresis analysis.
- Affinity Constants
- To determine the affinity of the antibodies to Adrenomedullin, the kinetics of binding of Adrenomedullin to immobilized antibody was determined by means of label-free surface plasmon resonance using a Biacore 2000 system (GE Healthcare Europe GmbH, Freiburg, Germany). Reversible immobilization of the antibodies was performed using an anti-mouse Fc antibody covalently coupled in high density to a CMS sensor surface according to the manufacturer's instructions (mouse antibody capture kit; GE Healthcare).
- Labelling procedure (tracer): 100 ug (100 ul) of antibody (1 mg/ml in PBS, pH 7.4,) was mixed with 10 ul Akridinium NHS-ester (1 mg/ml in acetonitrile, InVent GmbH, Germany) (57) and incubated for 20 min at room temperature. Labelled CT-H was purified by Gel-filtration HPLC on Bio-Sil® SEC 400-5 (Bio-Rad Laboratories, Inc., USA) The purified labeled antibody was diluted in (300 mmol/L potassiumphosphate, 100 mmol/L NaCl, 10 mmol/L Na-EDTA, 5 g/L Bovine Serum Albumin, pH 7.0). The final concentration was approx. 800.000 relative light units (RLU) of labelled compound (approx. 20 nglabeled antibody) per 200 μL. Akridiniumesterchemiluminescence was measured by using an AutoLumat LB 953 (Berthold Technologies GmbH & Co. KG).
- Solid phase: Polystyrene tubes (Greiner Bio-One International AG, Austria) were coated (18 h at room temperature) with antibody ((1.5 μg antibody/0.3
mL 100 mmol/L NaCl, 50 mmol/L TRIS/HCl, pH 7.8). After blocking with 5% bovine serum albumine, the tubes were washed with PBS, pH 7.4 and vacuum dried. -
- Calibrators:
- Synthetic human ADM (Bachem, Switzerland) was linearily diluted using 50 mMTris/HCl, 250 mMNaCl, 0.2% Triton X-100, 0.5% BSA, 20 tabs/L Protease cOmplete Protease Inhibitor Cocktail Tablets (Roche AG); pH 7.8. Calibrators were stored at −20° C. before use.
- Determination of the antibody combination that yields high signal/noise ratios
- ADM Immunoassay:
- 50 ul of sample (or calibrator) was pipetted into coated tubes, after adding labeleld second antibody (200 ul), the tubes were incubated for 2 h at room temperature. Unbound tracer was removed by washing 5 times (each 1 ml) with washing solution (20 mM PBS, pH 7.4, 0.1% Triton X-100).
- Tube-bound chemiluminescence was measured by using the LB 953
- All antibodies were used in a sandwich immunoassay as coated tube and labeled antibody and combined in the following variations (table 2):
- Incubation was performed as described under hADM-Immunoassay. Results are given in ratio of specific signal (at 10 ng/ml ADM)/background (sample without ADM) signal.
-
TABLE 2 Signal/ NT-ADM MR-ADM CT-ADM noise ratio tracer tracer tracer NT-ADM / 195 241 MRADM 204 / 904 CT-ADM 260 871 / - Surprisingly, we found the combination of MR-ADM and CT-ADM as combination for highest signal/noise ratio.
- Subsequently, we used this antibody-combination for further investigations. We used MR-ADM as solid phase antibody and CT-ADM as labeled antibody. A typical dose/signal curve is shown in
FIG. 1 . The analytical sensitivity (average of 10 runs, ADM-free sample+2SD) of the assay was 2 pg ADM/ml. - Stability of human Adrenomedullin:
- Human ADM was diluted in human Citrate plasma (n=5,
final concentration 10 ng ADM/ml) and incubated at 24° C. At selected time points, aliquots were frozen at −20° C. Immediately after thawing the samples hADM was quantified by using the hADM immunoassay described above. - Table 3 shows the stability of hADM in human plasma at 24° C.
-
Average ADM Relative Time recovery loss of immune Loss of immune (h) (N = 5) reactivity reactivity %/ h 0 100 / / 2 99.2 0.8 0.4 4 96.4 3.6 0.8 8 88.2 11.8 1.5 Average: 0.9%/h - Surprisingly, using the antibody-combinations MR-ADM and CT-ADM in a sandwich immune assay, the preanalytical stability of the analyte is high (only 0.9%/h average loss of immune reactivity). In contrast, using other assay methods, a plasma half life of only 22 min was reported (Hinson 2000). Since the time from taking sample to analysis in hospital routine is less than 2 h, the used ADM detection method is suitable for routine diagnosis. It is remarkable, that any non routine additives to samples (like Aprotinin, (20)) are not needed to reach acceptable ADM-immune reactivity stabilities.
- Reproducibility of calibrator-preparations.
- We found a high variation of results, preparing calibrators for ADM assays (average CV 8.5%, see table 4). This may be due to high adsorption of hADM to plastic and glass surfaces (see also (58). This effect was only slightly reduced by adding detergents (up to 1
% Triton X - Fortunately, the presence of N-terminal antibodies did not affect the ADM-signal generated by the combination of MR- and C-terminal antibodies (
FIG. 1 ). -
TABLE 4 In the presence Inter Inter of NT-ADM preparation preparation antibody CV Without CV calibrator (10 ug/ml) (%) antibody (%) 100 ng/ml 3453 s/n-r 0.9 2842 s/n-r 2.8 10 ng/ml 1946 s/n-r 0.8 1050 s/n-r 7.9 1 ng/ml 179 s/n-r 1.1 77 s/n-r 14.8 Average: 0.93 Average: 8.5 - Inter preparation variation of calibrators.
- ADM assay calibrators were prepared as described above with and without 10 ug/ml of NT-ADM-antibody. Coeffients of variation are given from 5 independent preparation runs. The calibrators were measured using the ADM assay described above. s/n-r=signal to noise ratio.
- For all following studies, we used an ADM assay, based on calibrators, prepared in the presence of 10 ug/ml of NT-ADM antibody and 10 ug/ml of NT-ADM antibody as supplement in the tracer buffer.
- Sensitivity
- The goal of assay sensitivity was to completely cover the ADM concentration of healthy subjects.
- ADM concentration in healthy subjects:
- Healthy subjects (n=100, average age 56 years) were measured using the ADM assay. The median value was 24.7 pg/ml, the lowest value 11 pg/ml and the 99th percentile 43 pg/ml. Since the assay sensitivity was 2 pg/ml, 100% of all healthy subjects were detectable using the described ADM assay.
- A commercial Assay was used to measure MR-proADM (BRAHMS MR-proADM KRYPTOR) (BRAHMS GmbH, Hennigsdorf, Germany) (ClinBiochem. 2009 May; 42(7-8):725-8. doi: 10.1016/j.clinbiochem.2009.01.002. Epub 2009 Jan. 23.
- Homogeneous time-resolved fluoroimmunoassay for the measurement of midregionalproadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR.Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B.)
- Clinical Study
- 101 ED patients fulfilling the definition of sepsis (Dellinger R P, Levy M M, Carlet J M, Bion J, Parker M M, Jaeschke R, Reinhart K, Angus D C, Brun-Buisson C, Beale R et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical care medicine 2008, 36(1):296-327.) were subsequently hospitalized (average 5 days of hospitalization) and received a standard of care treatment. EDTA-plasma was generated from day 1 (ED presentation) and one sample each day during hospital stay. The time to freeze samples for later ADM-measurement was less than 4 h. Patient characteristics are summarized in table 5
-
TABLE 5 all in hospitaldeaths discharged Variable (n = 101) (n = 27) (n = 74) p-value Demographics Gender - male 60 (60) 13 (48) 47 (64) 0.163 Age - median [IQR] 78 [72-72] 77 [71.25-83] 80 [75-84.5] 0.142 Examination variables BP systolic (mmHg) - 115 [100-100] 120 [106.25-138.75] 105 [80-120] 0.001 median [IQR] BP diastolic (mmHg) - 65 [60-60] 65 [60-85] 60 [50-70] 0.002 median [IQR] HR - median [IQR] 100 [94-94] 100 [94-114.75] 100 [93.5-107.5] 0.407 RR - median [IQR] 24 [22-22] 24 [22-28] 26 [24-28] 0.069 MAP (mmHg) - 83.3 [74-74] 83.3 [77.62-100.75] 81.6 [63.5-89] 0.026 median [IQR] concomitantdiseases Cardiovascular-yes 26 (25.7) 9 (33.3) 17 (23) 0.311 Hypertensive-yes 47 (46.5) 13 (48.1) 34 (45.9) 1.000 Diabetes -yes 35 (34.7) 9 (33.3) 26 (35.1) 1.000 Cancere-yes 13 (12.9) 3 (11.1) 10 (13.5) 1.000 routinelabaratory variables Blood culture-yes 31 (31) 5 (19) 26 (35) 0.246 negative 15 (16.3) 2 (8) 13 (19.4) positive 16 (17.4) 3 (12) 13 (19.4) Creatinine clearance 48 [23.25-23.25] 56 [29.25-80] 31.5 [14.75-66] 0.043 (ml/min) - median [IQR] Creatinine - median [IQR] 1.3 [0.9-0.9] 1.25 [0.9-2.08] 1.8 [1-3.15] 0.080 UREA - median [IQR] 36 [21-21] 31.5 [20-53.25] 51 [42-87] 0.004 GCS - median [IQR] 15 [10-10] 15 [12.5-15] 8 [8-11] <0.001 Pcr - median [IQR] 16 [6.6-6.6] 14.5 [6.7-23.7] 17.35 [6.6-28.05] 0.846 Gluco - median [IQR] 113.5 [94.5-94.5] 110 [95.5-144] 128 [94-160.5] 0.400 biliru - median [IQR] 0.9 [0.71-0.71] 0.9 [0.7-1.03] 0.91 [0.77-1.18] 0.534 GR - median [IQR] 3.8 [3.3-3.3] 3.8 [3.2-4.3] 3.7 [3.4-4.2] 0.684 GB - median [IQR] 12700 [6774-6774] 13100 [8115-17565] 11920 [25.55-18790] 0.343 PLT - median [IQR] 213 [150-150] 217 [154.75-301] 185 [130-236.5] 0.113 HCT - median [IQR] 32 [28-28] 31.5 [28-37] 34 [31.25-39.5] 0.149 Leuco/Neutr (%) - 87 [80-80] 86 [78.25-89.95] 91 [87-93.05] 0.001 median [IQR] HB - median [IQR] 10.4 [9.47-9.47] 10.15 [9.3-12.4] 10.85 [9.9-12.67] 0.220 Na - median [IQR] 137 [134-134] 137 [133-141] 139 [134-144.5] 0.204 K - median [IQR] 3.9 [3.5-3.5] 3.9 [3.6-4.3] 3.9 [3.3-5.1] 0.982 INR - median [IQR] 1.19 [1.1-1.1] 1.19 [1.1-1.4] 1.18 [1.04-1.36] 0.731 TC - median [IQR] 38.4 [36-36] 38.5 [38.12-38.7] 36 [35.55-38.5] <0.001 SAO2 - median [IQR] 94 [90-90] 95 [90.25-97] 93 [88.5-95.5] 0.119 pH - median [IQR] 7.45 [7.38-7.38] 7.46 [7.4-7.5] 7.4 [7.24-7.4] <0.001 PO2 - median [IQR] 67 [56-56] 66.5 [56-78] 67 [56.5-79.5] 0.806 PCO2 - median [IQR] 36 [32-32] 37.5 [33-43.75] 34 [30-41] 0.245 Lact - median [IQR] 1.5 [1-1] 1.3 [0.83-1.9] 2.5 [1.4-4.15] <0.001 Bic - median [IQR] 23.5 [21-21] 24.25 [21.43-28] 21 [17.35-23.25] 0.001 FiO2 (%) - median [IQR] 21 [21-21] 21 [21-23.25] 24 [21-45] <0.001 other Acuteorgandisfunction-yes 39 (43.3) 16 (64) 23 (35.4) 0.021 Apache score (%) - 19 [12.5-12.5] 14.65 [12.12-20.38] 32 [20-39] <0.001 median [IQR] Days hospitalized - 5 [2-2] 6 [4-7] 2 [1-6] 0.003 median [IQR] treatmentatbaseline Diuresis (cc) - 900 [600-600] 1000 [700-1200] 450 [200-1025] <0.001 median [IQR] Steroids -yes 16 (15.8) 4 (14.8) 12 (16.2) 1.000 Vasopressors-yes 18 (17.8) 13 (48.1) 5 (6.8) <0.001 Antibiotics-yes 101 (100) 27 (100) 74 (100) 1.000 Fluid therapy-yes 101 (100) 27 (100) 74 (100) 1.000 newbiomarker ADM (pg/mL) - 53.8 [37.4-94.0] 93.9 [48.7-241] 50.1 [32.2-77.8] <0.001 median [IQR] MR-proADM 0.54 [0.32-0.86] 0.98 [0.42-18.4] 0.46 [0.28-0.82] <0.001 (nmol/L) [IQR] - 26.7% of all patients died during hospital stay and are counted as treatment non-responder, 73.3% of all patients survived the sepsis and are counted as treatment responder.
- 66% off all patients presenting with sepsis had a non-normal ADM value >43 pg/ml (99 th percentile), indicating ADM not to be a marker for the infection.
- Results of Clinical Study
- Initial ADM is highly prognostic.
- We correlated the initial ADM value with the in-hospital mortality and compared ADM with APACHE 2 score. ADM is highly prognostic for sepsis outcome (see
FIG. 2 ) and comparable to APACHE 2 score. There is a significant added information if ADM and APACHE 2 are combined (FIG. 3 ). - ADM in treatment monitoring.
- Patients were treated based on standard of care treatments (table 5). The average hospitalization time was 5 days. ADM was measured each day in hospital (
day 1=admission) and correlated to in hospital mortality (table 6). ADM changed during hospital stay and the change during time improved the prognostic value by 52% from initial Chi2 of 19.2 to 29.2 on day 5. - Using a simple cut off model at 70 pg/ml of ADM showed a 68% risk of death for patients starting at ADM concentrations >70 pg/ml and remain all the hospital stay >70 pg/ml (treatment non-responder). Patients having all time an ADM value <70 pg/ml or developing from >70 pg/ml to <70 pg/ml had a mortality of only 11% (well treated/treatment responder) and patients presenting with ADM values >70 pg/ml and reducing their ADM concentration during hospital treatment to values <70 pg/ml had a 0% mortality. There were no patients developing from <70 pg/ml to >70 pg/ml during hospital treatment. The average time needed to generate responder/nonresponder information for all patients was about 1 day. The >70 pg/ml—patients responding to treatment during hospital stay needed about 2 days to indicate treatment success by ADM.
-
TABLE 6 Patients Patient all Patient all changed days >70 days <70 from >70 pg/ml pg/ml pg/ml to <70 pg/ml N 28/101 73/101 15/73 (27.7%) (72.3%) (20.5%) Mortality 68% 11% 0% Average days after 1 day 1.2 days 2.2 days hospitalization of change from ADM >70 pg/ml to ADM <70 pg/ml or no change - Relation of Plasma ADM with Mean Arterial Pressure (MAP) and need for Vasopressor Therapy
- We found a significant correlation of ADM concentrations with mean arterial pressure (
FIG. 4 ) and with the requirement for vasopressor therapy to treat/prevent shock (FIG. 5 ). - We also investigated the temporal relationship of ADM concentrations and the requirement for vasopressor therapy (
FIG. 6 ): Of the 101 patients investigated, already 18 required vasopressor therapy at admission; the median ADM concentration for these patients at admission was 129 pg/mL. Patients, who never required vasopressor therapy during their hospital stay within the first four days after admission (n=79), had a median ADM concentration of 48.5 pg/mL. Importantly, patients, who required vasopressor therapy during their hospital stay later than on admission had elevated ADM levels already at admission (median 87.2 pg/mL), e.g.: the elevation of plasma ADM concentration was preceding the vasopressor therapy. - In the plasma samples also MR-proADM, a stable fragment of the ADM precursor molecule, was measured. MR-proADM has been proposed as a surrogate marker for mature ADM release (Struck J, Tao C, Morgenthaler N G, Bergmann A: Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004, 25(8):1369-1372, Morgenthaler N G, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical chemistry 2005, 51(10):1823-1829). A commercial MR-proADM Assay was used (BRAHMS MR-proADM KRYPTOR) according to the instructions of the manufacturer (BRAHMS GmbH, Hennigsdorf, Germany). Median levels for the day of admission were 0.63 nmol/L for patients not requiring vasopressor therapy, and 1.57 nmol/L for patients requiring vasopressor therapy. Concentrations of MR-proADM were significantly correlated with concentrations of ADM (r=0.79).
- Cut off Analysis for Diagnosis and Prediction of Vasopressor need.
- Patient data see Example 6. The analysis was performed based on the first blood draw taken during emergency unit presentation of the sepsis patient.
- A cut off value of 70 pg/ml was selected, <70 pg/ml indicated a low risk of vasopressor need and >70 pg/ml indicated a high risk of vasopressor need.
Group 1 are patients not needed Vasopressors (MAP<=66 mmHg) nor received Vasopressors at presentation nor during a 4 day follow up period. Group 2 are Patients with Vasopressor need (MAP<=66 mmHg) or received Vasopressors at presentation. Group 3 are patients without Vasopressor need nor received Vasopressors at presentation but developed Vasopressor need during a 4 day follow up period. Patients (n=2) with missing information about Vasopressor treatment were excluded. -
TABLE 7 <70 pg/ml >70 pg/ml ADM ADM Group 1 56 15 79% specificity Group 2 3 18 89.5% sensitivity Group 3 2 5 71% correct classification - Using a simple cut off analysis at 70 pg/ml 89.5% of all patients needing vasopressors at ED presention were identified by ADM (group 2). There were 20 patients >70 pg/ml having no vasopressor need at presentation (
group 1/3), 15 (75%) did not developed vasopressor need during 4 day follow up and 5 (25%) of patients developed Vasopressor need during a 4 day follow up. In contrast, if ADM was <70pg/ml at patients without vasopressor need at presentation (Group 1/3), 56 (96.5%) did not developed vasopressor need during the 4 day follow up and only 2 (3.5%) developed a vasopressor need. The risk of developing vasopressor need during next 4 days of patients with an ADM value above 70 pg/ml is 7.1 times higher than for patients with ADM levels below 70 pg/ml (25% vs 3.5%). - Since blood pressure is always monitored, from a clinical point of view, patients with high ADM (>70pg/ml) without vasopressor need at presentation should be vasopressor treated by adapting the points of decision from <66 mmHg MAP to e.g. <75 mmHg aiming earlier support of circulation to protect patient from low blood pressure associated organ dysfunctions and subsequent high mortality. Using this rule for patients >70 pg/ml ADM and treating with vasopressors at MAP<=75 mmHg, patients (Group 3) would be treated in average 1,6 days before standard of care treatment (<=66mmHg).
- Similar results were obtained, when MR-proADM with a cut-off value of 0.78 noml/L was used in the analysis instead of ADM.
-
TABLE 8 <0.78 noml/L >0.78 noml/L MR-proADM MR- proADM Group 1 54 17 76.1% specificity Group 2 4 17 81% sensitivity Group 3 2 5 71% correct classification - Clinical Study/Acute Heart Failure
- Recruited patients were patients admitted to the emergency department with acute heart failure. Patient characteristics: Mean±SD age 74.3±12.2 y; n=1022 (643 male, 63%); previous Ischemic Heart Disease 31%, hypertension 58%, Diabetes 33%, Heart failure 35%. Patients were followed up for 2 years. Plasma samples for measurement of ADM and other analytes were gained on the day of admission.
- Cox analysis revealed that ADM was an independent predictor of 1 year death (table 9) and 1 year death/hospitalization due to acute decompensated Heart Failure (table 10). Logistic regression analysis revealed that ADM was an independent predictor of in hospital death (table 11).
- Patients who required vasopressor therapy (inotropes) had significantly higher ADM concentrations that all other patients (area under the curve=0.75; p<0001;
FIG. 7 ). -
TABLE 9 Hazard Ratio Hazard Ratio (P value) (P value) Univariate Multivariate Age 1.04 (<0.0005) 1.04 (<0.0005) Past history HF 1.48 (<0.001) N.S. Past history 1.79 (<0.0005) N.S. Renal failure Heart rate 0.99 (<0.003) N.S. Systolic BP 0.98 (<0.0005) 0.98 (<0.0005) Respiratory rate 1.02 (<0.0005) 1.02 (<0.001) NYHA 1.61 (<0.0005) N.S. Urea 1.03 (<0.0005) 1.05 (<0.0005) Creatinine 1.003 (<0.0005) N.S. Na 0.96 (<0.0005) 0.95 (<0.0005) NTproBNP 2.73 (<0.0005) N.S. ADM 3.92 (<0.0005) 2.35 (<0.0005) -
TABLE 10 Hazard Ratio Hazard Ratio (P value) (P value) Univariate Multivariate Age 1.02 (<0.0005) 1.02 (<0.001) Past history HF 1.72 (<0.001) 1.33 (<0.023) Past history 1.75 (<0.0005) N.S. Renal failure Heart rate 0.99 (<0.002) N.S. Systolic BP 0.99 (<0.0005) 0.99 (<0.012) Respiratory rate 1.01 (<0.008) 1.02 (<0.0005) NYHA 1.53 (<0.0005) 1.29 (<0.018) Urea 1.03 (<0.0005) 1.05 (<0.0005) Creatinine 1.002 (<0.0005) N.S. Na 0.98 (<0.012) 0.98 (<0.03) NTproBNP 1.82 (<0.0005) N.S. ADM 2.75 (<0.0005) 1.67 (<0.01) -
TABLE 11 Odds Ratio Odds Ratio (P value) (P value) Univariate Multivariate Age 1.04 (<0.001) 1.04 (<0.039) Past history HF 1.98 (<0.007) 1.33 (<0.023) Past history 2.71 (<0.0005) N.S. Renal failure Heart rate 0.99 (<0.074) N.S. Systolic BP 0.99 (<0.071) N.S. Respiratory rate N.S. NYHA 1.67 (<0.023) N.S. Urea 1.078 (<0.0005) 1.069 (<0.015) Creatinine 1.008 (<0.0005) N.S. Na 0.929 (<0.0005) 0.916 ((<0.0005) Troponin I N.S. N.S. NTproBNP 3.22 (<0.001) N.S. ADM 10.75 (<0.0005) 5.182 (<0.001) -
- (1) Kitamura, K., et al., “Adrenomedullin: A Novel Hypotensive Peptide Isolated From Human Pheochromocytoma”, Biochemical and Biophysical Research Communications, Vol. 192 (2), pp. 553-560 (1993).
- (2) Editorial, Takahashi, K., “Adrenomedullin: from a pheochromocytoma to the eyes”, Peptides, Vol. 22, p. 1691 (2001).
- (3) Eto, T., “A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-
terminal 20 peptide (PAMP), hypotensive and vasodilating peptides”, Peptides, Vol. 22, pp. 1693-1711 (2001). - (4) Hinson, et al., “ Adrenomedullin, a Multifunctional Regulatory Peptide”, Endocrine Reviews, Vol. 21(2), pp. 138-167 (2000).
- (5) Kitamura, K., et al., “The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma”, Biochem. Biophys. Res. Commun., Vol. 244(2), pp. 551-555 (1998). Abstract Only.
- (6) Pio, R., et al., “Complement Factor H is a Serum-binding Protein for Adrenomedulli, and the Resulting Complex Modulates the Bioactivities of Both Partners”, The Journal of Biological Chemistry, Vol. 276(15), pp. 12292-12300 (2001).
- (7) Kuwasako, K., et al., “Purification and characterization of PAMP-12 (PAMP-20) in porcine adrenal medulla as a major endogenous biologically active peptide”, FEBS Lett, Vol. 414(1), pp. 105-110 (1997). Abstract Only.
- (8) Kuwasaki, K., et al., “Increased plasma proadrenomedullin N-
terminal 20 peptide in patients with essential hypertension”, Ann. Clin. Biochem., Vol. 36 (Pt. 5), pp. 622-628 (1999). Abstract Only. - (9) Tsuruda, T., et al., “Secretion of proadrenomedullin N-
terminal 20 peptide from cultured neonatal rat cardiac cells”, Life Sci., Vol. 69(2), pp. 239-245 (2001). Abstract Only. - (10)
EP 0 622 458 A2, Shionogi & Co. Ltd.; Kangawa, Kenji - (11) Hirata, et al., “Increased Circulating Adrenomedullin, a Novel Vasodilatory Peptide, in Sepsis”, Journal of Clinical Endocrinology and Metabolism, Vol. 81(4), pp. 1449-1453 (1996).
- (12) Ehlenz, K., et al., “High levels of circulating adrenomedullin in severe illness: Correlation with C-reactive protein and evidence against the adrenal medulla as site of origin”, ExpClinEndocrinol Diabetes, Vol. 105, pp. 156-162 (1997).
- (13) Tomoda, Y., et al., “Regulation of adrenomedullin secretion from cultured cells”, Peptides, Vol. 22, pp. 1783-1794 (2001).
- (14) Ueda, S., et al., “Increased Plasma Levels of Adrenomedullin in Patients with Systemic Inflammatory Response Syndrome”, Am. J. Respir. Crit. Care Med., Vol. 160, pp. 132-136 (1999).
- (15) Wang, P., “Andrenomedullin and cardiovascular responses in sepsis”, Peptides, Vol. 22, pp. 1835-1840 (2001).
- (16) Wang P: Adrenomedullin in sepsis and septic shock. Shock 1998, 10(5):383-384.
- (17) Wang P, Ba Z F, Cioffi W G, Bland K I, Chaudry I H: The pivotal role of adrenomedullin in producing hyperdynamic circulation during the early stage of sepsis. Archives of surgery 1998, 133(12):1298-1304.
- (18) Parlapiano, C., et al.; “Adrenomedulin assay and its clinical significance”, European Review for Medical and Pharmacological Sciences, 1999; 3:53-61
- (19) Nishio K, Akai Y, Murao Y, Doi N, Ueda S, Tabuse H, Miyamoto S, Dohi K, Minamino N, Shoji H et al: Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Critical care medicine 1997, 25(6):953-957.
- (20) Krzeminski K, Mikulski T, Kruk B, Nazar K: Plasma adrenomedullin response to maximal exercise in healthy subjects. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 2003, 54(2):225-232.
- (21) Dellinger R P, Levy M M, Rhodes A, Annane D, Gerlach H, Opal S M, Sevransky J E, Sprung C L, Douglas I S, Jaeschke R et al: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical care medicine 2013, 41(2):580-637.
- (22) Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical care medicine 2001, 29(7):1303-1310.
- (23) Martin G S, Mannino D M, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. The New England journal of medicine 2003, 348(16):1546-1554.
- (24) Melamed A, Sorvillo F J: The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Critical care 2009, 13(1):R28.
- (25) Overgaard C B, Dzavik V: Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008, 118(10):1047-1056.
- (26) Bangash M N, Kong M L, Pearse R M: Use of inotropes and vasopressor agents in critically ill patients. British journal of pharmacology 2012, 165(7):2015-2033.
- (27) Boucheix O B, Milano S P, Henriksson M, Reinheimer T M: Selepressin, a New V1A Receptor Agonist: Hemodynamic Comparison to Vasopressin in Dogs. Shock 2013.
- (28) Bracht H, Calzia E, Georgieff M, Singer J, Radermacher P, Russell J A: Inotropes and vasopressors: more than haemodynamics! British journal of pharmacology 2012, 165(7):2009-2011.
- (29) Singer M, Coluzzi F, O'Brien A, Clapp L H: Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 2005, 365(9474):1873-1875.
- (30) Warrillow S, Egi M, Bellomo R: Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Critical care medicine 2006, 34(4):980-985.
- (31) Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J et al: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Critical care medicine 2004, 32(1):1-12.
- (32) Lopez A, Lorente J A, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Critical care medicine 2004, 32(1):21-30.
- (33) Kirov M Y, Evgenov O V, Evgenov N V, Egorina E M, Sovershaev M A, Sveinbjornsson B, Nedashkovsky E V, Bjertnaes L J: Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Critical care medicine 2001, 29(10):1860-1867.
- (34) Juffermans N P, Vervloet M G, Daemen-Gubbels C R, Binnekade J M, de Jong M, Groeneveld A B: A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric oxide: biology and chemistry/official journal of the Nitric Oxide Society 2010, 22(4):275-280.
- (35) Morgenthaler N G, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clinical chemistry 2005, 51(10):1823-1829.
- (36) Struck J, Tao C, Morgenthaler NG, Bergmann A: Identification of an
- Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004, 25(8):1369-1372.
Claims (14)
1-20. (canceled)
21. A composition comprising:
a complex comprising at least one binder to proADM (SEQ ID No. 1) and/or fragments and at least one binder to MR-proADM and/or fragments thereof,
sample of bodily fluid obtained from a subject who is not suffering from a physiological shock state,
wherein the complex contains more than 70 pg/ml of proADM (SEQ ID No. 1) and/or fragments, and/or its isoforms and more than 0.7 nmol/L of plasma MR-proADM and/or fragments thereof within said composition.
22. The composition of claim 21 , wherein said proADM (SEQ ID No. 1) and/or fragments thereof having at least 6 amino acids are selected from the group comprising mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5) and MR-proADM (SEQ ID No.3) and CT-ADM (SEQ ID No. 6).
23. The composition of claim 22 wherein either a level of mature ADM (SEQ ID No. 4) immunoreactivity and/or a level of mature ADM 1-52-Gly (SEQ ID No. 5)—immunoreactivity or a level of MR-proADM (SEQ ID No.3) immunoreactivity or a level of CT-ADM (SEQ ID No.6) immunoreactivity is above a threshold.
24. The composition of claim 21 , wherein the level of pro-ADM (SEQ ID No. 1) and/or fragments thereof is measured by using at least one binder selected from the group consisting of a binder that binds to a region comprised within the following sequence of mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5) and a second binder that binds to a region comprised within the following sequence of mature ADM (SEQ ID No. 4) and/or mature ADM 1-52-Gly (SEQ ID No. 5).
25. The composition of claim 21 , wherein the level of pro-ADM (SEQ ID No. 1) and/or fragments thereof is measured by using at least one binder selected from the group consisting of a binder that binds to a region comprised within the following sequence of MR-proADM (SEQ ID No. 3) and a second binder that binds to a region comprised within the following sequence of MR-proADM (SEQ ID No. 3)
26. The composition of claim 21 , wherein the level of pro-ADM (SEQ ID No. 1) and/or fragments thereof is measured by using at least one binder selected from the group consisting of a binder that binds to a region comprised within the following sequence of CT-proADM (SEQ ID No. 6) and a second binder that binds to a region comprised within the following sequence of CT-proADM (SEQ ID No. 6).
27. The composition of claim 21 , wherein an assay is used for measuring the level of proADM (SEQ ID No.1) and/or fragments thereof having at least 6 amino acids wherein the assay sensitivity of said assay is able to quantify the ADM of healthy subjects and is <70 pg/ml.
28. The composition of claim 21 , wherein said binders exhibits a binding affinity to proADM (SEQ ID No. 1) and/or fragments thereof of at least 107 M−1.
29. The composition of claim 21 , wherein said binders are selected from the group consisting of an antibody or an antibody fragment and a non-Ig scaffold binding to proADM (SEQ ID No. 1) and/or fragments thereof.
30. The composition of claim 27 , wherein said assay is a sandwich assay.
31. The composition of claim 21 , wherein said binders are labeled in order to be detected.
32. The composition of claim 21 , wherein at least one of said binders is bound to a solid phase.
33. The composition of claim 21 , wherein said sample of bodily fluid is selected from the group consisting of human citrate plasma, heparin plasma, EDTA plasma, whole blood, and serum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/781,226 US20200249246A1 (en) | 2013-03-20 | 2020-02-04 | Adrenomedullin to guide therapy of blood pressure decline |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13160265 | 2013-03-20 | ||
EP13160265.8 | 2013-03-20 | ||
PCT/EP2014/055554 WO2014147153A1 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
US201514778114A | 2015-09-18 | 2015-09-18 | |
US16/781,226 US20200249246A1 (en) | 2013-03-20 | 2020-02-04 | Adrenomedullin to guide therapy of blood pressure decline |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/778,114 Division US10598674B2 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
PCT/EP2014/055554 Division WO2014147153A1 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200249246A1 true US20200249246A1 (en) | 2020-08-06 |
Family
ID=47901848
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/778,114 Active US10598674B2 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
US16/781,226 Pending US20200249246A1 (en) | 2013-03-20 | 2020-02-04 | Adrenomedullin to guide therapy of blood pressure decline |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/778,114 Active US10598674B2 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
Country Status (11)
Country | Link |
---|---|
US (2) | US10598674B2 (en) |
EP (1) | EP2976646B1 (en) |
JP (3) | JP6259905B2 (en) |
CN (2) | CN108362885B (en) |
CA (1) | CA2907467A1 (en) |
DK (1) | DK2976646T3 (en) |
ES (1) | ES2830036T3 (en) |
HK (2) | HK1216264A1 (en) |
RU (1) | RU2673455C2 (en) |
SG (2) | SG10201800309SA (en) |
WO (1) | WO2014147153A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3380845A1 (en) * | 2015-11-27 | 2018-10-03 | B.R.A.H.M.S GmbH | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT |
SG11201900133WA (en) * | 2016-07-08 | 2019-02-27 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
JP6855118B2 (en) * | 2017-03-14 | 2021-04-07 | 東ソー株式会社 | Methods and measurement reagents that provide information for assessing the quality of general condition |
JP7001285B2 (en) * | 2017-03-29 | 2022-01-19 | 国立大学法人 宮崎大学 | Long-acting adrenomedulin derivative |
CN107194129B (en) * | 2017-06-30 | 2019-08-06 | 江南大学 | A method of using the modified ADM1 model analysis kitchen garbage methane phase of lactic acid |
EP3438668A1 (en) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
EP3682236A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
DK3682247T3 (en) | 2017-09-13 | 2022-03-21 | Brahms Gmbh | PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL BLOOD PLATE LEVELS |
JP7258860B2 (en) * | 2017-09-13 | 2023-04-17 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | PCT and PRO-ADM as markers for monitoring antibiotic therapy |
CA3075440A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
EP3854414A1 (en) * | 2017-09-25 | 2021-07-28 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
BR112020005682A2 (en) * | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoring therapy under treatment with an antiadrenomedullin binder (adm) |
EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
US20210109118A1 (en) * | 2017-12-20 | 2021-04-15 | B.R.A.H.M.S Gmbh | Antibiotic therapy guidance based on pro-adm |
EP3578989A1 (en) * | 2018-06-06 | 2019-12-11 | B.R.A.H.M.S GmbH | Pro-adm for prognosis of trauma-related complications in polytrauma patients |
CA3119792A1 (en) * | 2018-11-15 | 2020-05-22 | Ferring B.V. | Compounds, compositions and methods for treating sepsis |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8519425D0 (en) | 1985-08-01 | 1985-09-04 | Ici Plc | Amine production |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ATE356869T1 (en) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
JP2774769B2 (en) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | Adrenomedullin |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
IL160289A0 (en) | 2001-08-30 | 2004-07-25 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins |
ES2372978T3 (en) | 2002-06-07 | 2012-01-30 | Dyax Corp. | POLYPEPTIDE WITH MODIFIED KUNITZ DOMAIN. |
DE10316583A1 (en) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination |
US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
JP2009510478A (en) * | 2005-10-03 | 2009-03-12 | バイオサイト インコーポレイテッド | Methods and compositions for diagnosis and / or prognosis of systemic inflammatory response syndrome |
US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
DE102006060112A1 (en) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using the new marker CT-proADM |
WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
ES2373832T3 (en) | 2007-12-19 | 2012-02-09 | Affibody Ab | POLYPEPTIDE DERIVED FROM PROTEIN A AND ABLE TO JOIN PDGF. |
US20090304673A1 (en) * | 2008-06-10 | 2009-12-10 | Bernd Buchberger | Method of Treatment of Inflammatory Diseases |
KR101698362B1 (en) | 2008-11-03 | 2017-01-20 | 몰리큘라 파트너스 아게 | Binding proteins inhibiting the VEGF-A receptor interaction |
EP2470556B1 (en) | 2009-08-27 | 2018-05-30 | Covagen AG | Il-17 binding compounds and medical uses thereof |
CA2778872C (en) | 2009-12-14 | 2015-06-02 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
EP2580236B1 (en) | 2010-06-08 | 2019-04-03 | Pieris Pharmaceuticals GmbH | Tear lipocalin muteins binding il-4 r alpha |
EP2583106A1 (en) * | 2010-06-18 | 2013-04-24 | Cézanne S.A.S. | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
-
2014
- 2014-03-19 CN CN201810035720.XA patent/CN108362885B/en active Active
- 2014-03-19 EP EP14711741.0A patent/EP2976646B1/en active Active
- 2014-03-19 JP JP2016504582A patent/JP6259905B2/en active Active
- 2014-03-19 RU RU2015144699A patent/RU2673455C2/en active
- 2014-03-19 CN CN201480010451.1A patent/CN105102985B/en active Active
- 2014-03-19 US US14/778,114 patent/US10598674B2/en active Active
- 2014-03-19 ES ES14711741T patent/ES2830036T3/en active Active
- 2014-03-19 WO PCT/EP2014/055554 patent/WO2014147153A1/en active Application Filing
- 2014-03-19 SG SG10201800309SA patent/SG10201800309SA/en unknown
- 2014-03-19 CA CA2907467A patent/CA2907467A1/en active Pending
- 2014-03-19 DK DK14711741.0T patent/DK2976646T3/en active
- 2014-03-19 SG SG11201507774YA patent/SG11201507774YA/en unknown
-
2016
- 2016-04-13 HK HK16104224.2A patent/HK1216264A1/en unknown
-
2017
- 2017-12-11 JP JP2017236881A patent/JP2018059947A/en not_active Ceased
-
2019
- 2019-01-17 HK HK19100872.2A patent/HK1258520A1/en unknown
- 2019-12-25 JP JP2019234773A patent/JP6820399B2/en active Active
-
2020
- 2020-02-04 US US16/781,226 patent/US20200249246A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108362885B (en) | 2021-05-14 |
CN108362885A (en) | 2018-08-03 |
WO2014147153A1 (en) | 2014-09-25 |
SG11201507774YA (en) | 2015-10-29 |
JP6820399B2 (en) | 2021-01-27 |
RU2015144699A (en) | 2017-04-28 |
CN105102985A (en) | 2015-11-25 |
EP2976646B1 (en) | 2020-08-19 |
SG10201800309SA (en) | 2018-02-27 |
US10598674B2 (en) | 2020-03-24 |
HK1258520A1 (en) | 2019-11-15 |
JP2016521351A (en) | 2016-07-21 |
EP2976646A1 (en) | 2016-01-27 |
ES2830036T3 (en) | 2021-06-02 |
HK1216264A1 (en) | 2016-10-28 |
US20170010286A1 (en) | 2017-01-12 |
JP2018059947A (en) | 2018-04-12 |
CN105102985B (en) | 2018-05-18 |
DK2976646T3 (en) | 2020-11-16 |
JP6259905B2 (en) | 2018-01-10 |
CA2907467A1 (en) | 2014-09-25 |
RU2673455C2 (en) | 2018-11-27 |
JP2020073896A (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200249246A1 (en) | Adrenomedullin to guide therapy of blood pressure decline | |
US9535060B2 (en) | Adrenomedullin assays and methods for determining mature adrenomedullin | |
US20190010226A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
US20240085438A1 (en) | Adrenomedullin assays and methods for determining mature andrendomedullin | |
US20140322225A1 (en) | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
US20220268761A1 (en) | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder | |
EP3482208B1 (en) | Adrenomedullin for assessing congestion in a subject with acute heart failure | |
US20230104578A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock | |
RU2776811C2 (en) | Therapy monitoring in treatment with binding agent against adrenomedullin (adm) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |